Alzheimer’s disease: a review on the current trends of the effective diagnosis and therapeutics
Frontiers in Aging Neuroscience,
Journal Year:
2024,
Volume and Issue:
16
Published: Aug. 9, 2024
The
most
prevalent
cause
of
dementia
is
Alzheimer's
disease.
Cognitive
decline
and
accelerating
memory
loss
characterize
it.
disease
advances
sequentially,
starting
with
preclinical
stages,
followed
by
mild
cognitive
and/or
behavioral
impairment,
ultimately
leading
to
dementia.
In
recent
years,
healthcare
providers
have
been
advised
make
an
earlier
diagnosis
Alzheimer's,
prior
individuals
developing
Regrettably,
the
identification
early-stage
in
clinical
settings
can
be
arduous
due
tendency
patients
disregard
symptoms
as
typical
signs
aging.
Therefore,
accurate
prompt
essential
order
facilitate
development
disease-modifying
secondary
preventive
therapies
onset
symptoms.
There
has
a
notable
shift
goal
process,
transitioning
from
merely
confirming
presence
symptomatic
AD
recognizing
illness
its
early,
asymptomatic
phases.
Understanding
evolution
putting
effective
diagnostic
therapeutic
management
into
practice
requires
understanding
this
concept.
outcomes
study
will
enhance
in-depth
knowledge
current
status
disease's
treatment,
justifying
necessity
for
quest
potential
novel
biomarkers
that
contribute
determining
stage
disease,
particularly
earliest
stages.
Interestingly,
latest
trial
on
pharmacological
agents,
nonpharmacological
treatments
such
behavior
modification,
exercise,
training
well
alternative
approach
phytochemicals
neuroprotective
agents
covered
detailed.
Language: Английский
Non-Drug and Non-Invasive Therapeutic Options in Alzheimer’s Disease
Biomedicines,
Journal Year:
2025,
Volume and Issue:
13(1), P. 84 - 84
Published: Jan. 1, 2025
Despite
the
massive
efforts
of
modern
medicine
to
stop
evolution
Alzheimer’s
disease
(AD),
it
affects
an
increasing
number
people,
changing
individual
lives
and
imposing
itself
as
a
burden
on
families
health
systems.
Considering
that
vast
majority
conventional
drug
therapies
did
not
lead
expected
results,
this
review
will
discuss
newly
developing
alternative
in
effort
or
slow
AD.
Focused
Ultrasound
(FUS)
its
derived
Transcranial
Pulse
Stimulation
(TPS)
are
non-invasive
therapeutic
approaches.
Singly
applied
technique
change
permeability
blood–brain–barrier
(BBB),
FUS
TPS
have
demonstrated
benefits
use
treating
AD
animal
human
studies.
Adipose-derived
stem
Cells
(ADSCs),
gene
therapy,
many
other
methods
(diet,
sleep
pattern,
physical
exercise,
nanoparticle
delivery)
also
new
potential
treatments
since
multimodal
approaches
represent
trend
disorder
research
therapies.
Language: Английский
Metformin Improves Spatial Memory and Reduces Seizure Severity in a Rat Model of Epilepsy and Alzheimer’s Disease comorbidity via PI3K/Akt Signaling Pathway
Suélen Santos Alves,
No information about this author
Letícia Rossi,
No information about this author
José Antônio Cortes de Oliveira
No information about this author
et al.
Molecular Neurobiology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 24, 2025
Language: Английский
From Plaques to Pathways in Alzheimer’s Disease: The Mitochondrial-Neurovascular-Metabolic Hypothesis
Sarah Kazemeini,
No information about this author
Ahmed Nadeem-Tariq,
No information about this author
Ryan M. Shih
No information about this author
et al.
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(21), P. 11720 - 11720
Published: Oct. 31, 2024
Alzheimer's
disease
(AD)
presents
a
public
health
challenge
due
to
its
progressive
neurodegeneration,
cognitive
decline,
and
memory
loss.
The
amyloid
cascade
hypothesis,
which
postulates
that
the
accumulation
of
amyloid-beta
(Aβ)
peptides
initiates
leading
AD,
has
dominated
research
therapeutic
strategies.
failure
recent
Aβ-targeted
therapies
yield
conclusive
benefits
necessitates
further
exploration
AD
pathology.
This
review
proposes
Mitochondrial-Neurovascular-Metabolic
(MNM)
integrates
mitochondrial
dysfunction,
impaired
neurovascular
regulation,
systemic
metabolic
disturbances
as
interrelated
contributors
pathogenesis.
Mitochondrial
hallmark
leads
oxidative
stress
bioenergetic
failure.
Concurrently,
breakdown
blood-brain
barrier
(BBB)
cerebral
blood
flow,
characterize
dysregulation,
accelerate
neurodegeneration.
Metabolic
such
glucose
hypometabolism
insulin
resistance
impair
neuronal
function
survival.
hypothesis
highlights
interconnectedness
these
pathways
suggests
strategies
targeting
health,
integrity,
regulation
may
offer
more
effective
interventions.
MNM
addresses
multifaceted
aspects
providing
comprehensive
framework
for
understanding
progression
developing
novel
approaches.
approach
paves
way
innovative
could
significantly
improve
outcomes
millions
affected
worldwide.
Language: Английский
From Mild Cognitive Impairment to Dementia: The Impact of Comorbid Conditions on Disease Conversion
Biomedicines,
Journal Year:
2024,
Volume and Issue:
12(8), P. 1675 - 1675
Published: July 26, 2024
The
conversion
from
mild
cognitive
impairment
(MCI)
to
dementia
is
influenced
by
several
factors,
including
comorbid
conditions
such
as
metabolic
and
vascular
diseases.
Understanding
the
impact
of
these
comorbidities
can
help
in
disease
management
patients
with
a
higher
risk
progressing
dementia,
improving
outcomes.
In
current
study,
we
aimed
analyze
data
large
cohort
MCI
(n
=
188)
principal
component
analysis
(PCA)
cluster
(CA)
classify
into
distinct
groups
based
on
their
comorbidity
profile
predict
dementia.
From
our
analysis,
four
clusters
emerged.
CA
showed
significantly
rate
progression
for
Cluster
1,
which
was
predominantly
characterized
extremely
high
obesity
diabetes
compared
other
clusters.
contrast,
3,
defined
lower
prevalence
all
comorbidities,
had
rate.
2,
mainly
subjects
traumatic
brain
injuries,
lowest
conversion.
Lastly,
4,
load
hearing
loss
depression,
an
intermediate
This
study
underscores
significant
specific
profiles
highlighting
need
targeted
interventions
strategies
individuals
potentially
delay
or
prevent
onset
Language: Английский